NICO Corporation Adds to Strong Intellectual Property Portfolio of 200+ with New Patent Issued Around Revolutionary BrainPath Technology

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

NICO Corporation announced they have  invested more than 10 years building, perfecting and protecting its diverse intellectual property (IP) portfolio encompassing technologies and methodologies around a better way of performing minimally disruptive brain surgery. One of the company’s most recent patents issued today provides for additional protection around its unique brain access technology, BrainPath – the world’s first and only technology that accesses the brain through the sulcus, or natural opening in the brain.

Joe Mark, Chief Technology Officer of NICO and primary inventor of its patented technologies comments:  “This new issuance further protects the distinctive capabilities of the BrainPath technology and is validation by the patent office that these innovations are relevant and worthy of protecting.”  He added, “Our goal has been to develop technologies that can be used as part of a systems approach to achieve the long desired goal of non-destructive trans-sulcal access to the subcortical space. We have accomplished this goal and our bibliography of more than 60 independently published papers and abstracts suggests that these innovations contribute to improved patient outcomes.”

Patent number 10,022,520 specifically provides for additional protection of BrainPath, including:

  • An introducing obturator whereby a third-party navigational probe is configured to be selectively integrated with the introducing obturator;
  • An introducing obturator whereby a third-party navigational probe is precluded from extending beyond the introducing obturator

BrainPath is designed to be a deficit-sparing device that is introduced parallel to the brain’s delicate anatomy and is guided by navigation, allowing the physician guided, non-disruptive access to the brain.

“Non-disruptive access in any surgical specialty opens the door to innovation, improved outcomes and propels the field forward,” said Jim Pearson, NICO President and CEO. “What NICO’s technologies accomplish for neurosurgery is much like when arthroscopic knee surgery came to orthopedics – it revolutionized what was possible.”

NICO’s strong IP portfolio is centered around a systematic approach to minimally disruptive access, automated tissue removal and hemorrhage evacuation, and intraoperative tissue harvesting and biological preservation. The basis for the portfolio is to protect and build upon technologies designed to deliver improved clinical and economic outcomes for healthcare providers.

“Much of it starts with not having preconceived notions about limitations. I don’t ask why we can’t do something, I ask how can we achieve a desired outcome that is better for the neurosurgeon, the hospital and the patient,” Mark said. “My job is to think about the clinical needs and all possible solutions before anyone else does – solutions that truly meet an unmet need and provide strong commercial and patent opportunities for NICO.”

NICO’s U.S. and international patent portfolio now totals more than 200 patents. The company has made a significant investment in IP applications because of the high value placed on protecting the unique surgical approach and added surgical options they bring to the market.

“We have been very deliberate about investing in and building fences around our innovative technologies,” said Pearson. “We have been and will continue to be forward-thinking about how we protect our concepts and methods.”

Additional information about the BrainPath Approach and other NICO technologies at



Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.